The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone

Breast Cancer

Volumn 20, Issue 3, 2013, Pages 241-246

  Asanuma, Kunihiro ^a   Wakabayashi, Hiroki ^a   Okamoto, Takayuki ^a   Asanuma, Yumiko ^a   Akita, Nobuyuki ^a   Yoshikawa, Tomoaki ^a   Hayashi, Tatsuya ^a   Matsumine, Akihiko ^a   Uchida, Atsumasa ^a   Sudo, Akihiro ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Argatroban; Bone metastasis; Breast cancer; Thrombin; Thrombin inhibitor

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR 10; SODIUM CHLORIDE; THROMBIN; THROMBOPLASTIN; VASCULOTROPIN; ANTITHROMBIN; PIPECOLIC ACID DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE MODEL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART LEFT VENTRICLE; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; BONE NEOPLASMS; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; HUMAN; METABOLISM; PATHOLOGY; SECONDARY; TUMOR CELL CULTURE;

ANIMALS; ANTITHROMBINS; BODY WEIGHT; BONE NEOPLASMS; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MICE; PIPECOLIC ACIDS; THROMBIN; THROMBOPLASTIN; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880037961     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0334-5     Document Type: Article

References (32)

1. Gordon SG. Cancer cell procoagulants and their role in malignant disease. Semin Thromb Hemost. 1992;18(4):424-33. (Pubitemid 23190621)
2. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: trousseau's syndrome revisited. Blood. 1983;62(1):14.
3. Rao LV. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev. 1992;11(3-4):249.
4. Murray JC. Coagulation and cancer. Br J Cancer. 1991;64(3):422-4.
5. Costantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost. 1993;69(5):406-14. (Pubitemid 23146431)
6. Nierodzik MLR, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res. 1992;52(12):3267-72.
7. Zain J, Huang YQ, Feng XS, Nierodzik ML, Li JJ, Karpatkin S. Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells. Blood. 2000;95(10):3133.
8. Henrikson KP, Salazar SL, Fenton JW, Pentecost BT. Role of thrombin receptor in breast cancer invasiveness. Br J Cancer. 1999;79(3-4):401-6. (Pubitemid 29046211)
9. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998;4(8):909-14. (Pubitemid 28364029)
10. Liu Y, Mueller BM. Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. Biochem Biophys Res Commun. 2006;344(4):1263-70.
11. BelAiba RS, Djordjevic T, Bonello S, Artunc F, Lang F, Hess J, et al. The serum- and glucocorticoid-inducible kinase Sgk-1 is involved in pulmonary vascular remodeling: role in redox-sensitive regulation of tissue factor by thrombin. Circ Res. 2006;98(6):828-36.
12. Escolar G, Bozzo J, Maragall S. Argatroban: a direct thrombin inhibitor with reliable and predictable anticoagulant actions. Drugs Today. 2006;42(4):223-36. (Pubitemid 43901685)
13. Asanuma K, Wakabayashi H, Hayashi T, Okuyama N, Seto M, Matsumine A, et al. Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology. 2004;67(2):166-73. (Pubitemid 39482686)
14. Deguchi H, Takeya H, Wada H, Gabazza EC, Hayashi N, Urano H, et al. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood. 1997;90(6):2345-56. (Pubitemid 27392718)
15. Ollivier V, Chabbat J, Herbert JM, Hakim J, De Prost D. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol. 2000;20:1374-81. (Pubitemid 30262941)
16. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000;83(2):164-70. (Pubitemid 30411712)
17. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci. 1995;92(18):8205-9.
18. Booden MA, Eckert LB, Der CJ, Trejo JA. Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol. 2004;24(5):1990-9. (Pubitemid 38248939)
19. Liu J, Schuff-Werner P, Steiner M. Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells. Biochem Biophys Res Commun. 2006;343(1):183-9.
20. Ge L, Shenoy SK, Lefkowitz RJ, DeFea K. Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. J Biol Chem. 2004;279(53):55419-24. (Pubitemid 40066542)
21. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302-9.
22. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1-8.
23. Harris AL, Zhang H, Moghaddam A, Fox S, Scott P, Pattison A, et al. Breast cancer angiogenesis new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Res Treat. 1996;38(1):97-108. (Pubitemid 26031068)
24. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, et al. Breast carcinoma vascular density determined using CD105 antibody correlates with tumor prognosis 1. Cancer Res. 1999;59(4):856-61. (Pubitemid 29086739)
25. Goede V, Fleckenstein G, Dietrich M, Osmers RGW, Kuhn W, Augustin HG. Prognostic value of angiogenesis in mammary tumors. Anticancer Res. 1998;18(3C):2199-202. (Pubitemid 28386488)
26. Heimann R, Ferguson D, Gray S, Hellman S. Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis. Breast Cancer Res Treat. 1998;52:147-58. (Pubitemid 29056092)
27. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306-9. (Pubitemid 20066716)
28. Sachdev JC, Jahanzeb M. Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer. 2008;8(5):402-10.
29. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008;14(17):5459.
30. Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther. 2009;8(7):1761.
31. Mohle R, Green D, Moore MAS, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Natl Acad Sci. 1997;94:663-8. (Pubitemid 27053690)
32. Schulze EB, Hedley BD, Goodale D, Postenka CO, Al-Katib W, Tuck AB, et al. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat. 2008;112(2):243-54.